Aurinia Q2: LUPKYNIS Sales Climb 19% to $79.4M, Net Income Soars 74%

summarizeSummary

Aurinia reported Q2 2026 revenue of $83.2 million, up 19%, driven by LUPKYNIS sales of $79.4 million. Net income rose 74% to $37.4 million, and the company reiterated full-year guidance of $315–$325 million in total revenue.

check_boxKey Events · Earnings and Guidance · AUPH

• LUPKYNIS Sales Accelerate

  Net product sales of LUPKYNIS reached $79.4 million in Q2 2026, a 19% increase year-over-year, driven by growing demand for the first FDA-approved oral therapy for active lupus nephritis.

• Profitability Surges

  Net income jumped 74% to $37.4 million, with diluted EPS of $0.28, reflecting strong operating leverage and a 19% increase in operating cash flow to $52.5 million.

• Robust Cash Position

  Cash, cash equivalents, restricted cash and investments totaled $443.1 million as of June 30, 2026, after repurchasing 5.0 million shares for $74.9 million during the first half of the year.

• Full-Year Guidance Reiterated

  Management reaffirmed 2026 total revenue guidance of $315–$325 million and net product sales guidance of $305–$315 million, implying 11–15% growth over 2025.

auto_awesomeAnalysis · AUPH · Life Sciences

A strong second quarter saw LUPKYNIS net product sales accelerate to $79.4 million, a 19% year-over-year gain that lifted total revenue to $83.2 million. Net income surged 74% to $37.4 million, and the company generated $52.5 million in operating cash flow for the period. The balance sheet remains robust with $443.1 million in cash and investments, even after repurchasing $74.9 million in shares. Management reiterated full-year revenue guidance of $315–$325 million, signaling confidence in sustained growth. The pipeline also advanced, with the initiation of a Phase 4 combination study for LUPKYNIS and clinical development of aritinercept in four autoimmune indications. These results reinforce Aurinia's transition to a profitable, cash-generating commercial-stage biotech.